Dupont DE Nemours
DUPONT DE NEMOURS, INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$6.8B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
64.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-14.1%
Capital efficiency
★☆☆☆☆position among all companies
-5.6%
Revenue and profit
Performance, financial position and capital allocation
Dupont DE Nemours
Recent performance trends
Dupont DE Nemours
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$12.6 billion | US$13.0 billion | US$6.6 billion | US$6.7 billion | US$6.8 billion |
| Net income | US$6.5 billion | US$5.9 billion | US$0.4 billion | US$0.7 billion | US$-0.8 billion |
| Total assets | US$45.7 billion | US$41.4 billion | US$38.6 billion | US$36.6 billion | US$21.6 billion |
| Shareholders' equity | US$26.4 billion | US$26.6 billion | US$24.3 billion | US$23.4 billion | US$13.9 billion |
| Net cash provided by (used in) operating activities | US$1.8 billion | US$1.2 billion | US$0.8 billion | US$0.8 billion | US$0.6 billion |
| Net cash provided by (used in) investing activities | US$-2.3 billion | US$9.0 billion | US$0.5 billion | US$-0.6 billion | US$-0.4 billion |
| Net cash provided by (used in) financing activities | US$-7.6 billion | US$-7.6 billion | US$-3.0 billion | US$-1.8 billion | US$-1.8 billion |
| Cash and cash equivalents | US$2.0 billion | US$3.7 billion | US$2.4 billion | US$1.8 billion | US$0.7 billion |
Revenue scale in the same industry
Dupont DE Nemours
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 27 companies
- 31 The CloroxFY Jun 2025 US$7.1B
- 32 CF Industries HoldingsFY Dec 2025 US$7.1B
- 33 Dupont DE NemoursThis companyFY Dec 2025 US$6.8B
- 34 OlinFY Dec 2025 US$6.8B
- 35 OrganonFY Dec 2025 US$6.2B
- … 21 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.3 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.6 billion | Consolidated | Disclosed |
| Dividends paid | US$0.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$14.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.2 billion | Consolidated | Disclosed |
| Net assets | US$13.9 billion | Consolidated | Disclosed |
| Net sales | US$6.8 billion | Consolidated | Disclosed |
| Net income | US$-0.8 billion | Consolidated | Disclosed |
| Total assets | US$21.6 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 64.5% | Consolidated | Calculated |
| Net margin | -11.4% | Consolidated | Calculated |
| Return on equity | -5.6% | Consolidated | Calculated |